A Prospective Randomized Trial on Mycophenolate Mofetil in Risk Penetrating Keratoplasty
The purpose of this prospectively randomized multicentre study was to prove the efficacy and safety of mycophenolate mofetil (MMF) to preventing graft rejection and improvement of clear graft survival following high-risk keratoplasty.
The patients of the MMF group receive MMF orally 2x1 g daily for 6 months. Endpoints were immune reaction free and clear graft survival and the occurence of side-effects.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Please refer to this study by its ClinicalTrials.gov identifier: NCT00411515
|University Eye hospital|
|Freiburg, Germany, 79106|
|Study Chair:||Thomas Reinhard, Prof. MD||University Eye Hospital, Freiburg|